



# GOG PARTNERS CONNECTION

A Quarterly Newsletter

From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission that is dedicated to transforming the standard of care in gynecologic oncology.

## INCLUSION, DIVERSITY, EQUITY, and ACCESS (IDEA) COMMITMENT

Collaborating to Raise Awareness, Educate, and Encourage  
Participation of Underrepresented Patients in Clinical Trials

The GOG Foundation, Inc. (GOG-F) announced the new IDEA Commitment initiative on Thursday, February 15, 2024 at the NRG Semi-Annual Meeting in Orlando, Florida.



The GOG-F has invested in the IDEA Commitment to:

- Increase awareness about the importance of diversity in clinical trials,
- Identify barriers to enrolling underrepresented patients,
- And design clinical trials in partnership with industry that demonstrate a commitment to inclusion, diversity, equity and access for all patients.

The IDEA Commitment efforts of improving diversity in clinical trials will focus on Education, Access, Policy, and Research.

Click the video below to view the Welcome & Introduction to the IDEA Commitment with Dr. Thomas Herzog, President of The GOG Foundation, Inc., and Dr. Bhavana Pothuri, Director of Diversity & Health Equity for Clinical Trials for The GOG Foundation, Inc.

## IDEA COMMITMENT



**Thomas Herzog, MD**  
President  
The GOG Foundation, Inc.



**Bhavana Pothuri**  
Director of Diversity & Inclusion Equity for Clinical Trials  
The GOG Foundation, Inc.



**IDEA**  
COMMITMENT

*Collaborating to Raise Awareness, Educate, and Encourage  
Participation of Underrepresented Patients in Clinical Trials*

[Click here](#) for more information on the IDEA Commitment!

## SGO/GOG-F BRIDGES 2.0 RESEARCH INITIATIVE

### With Support from the FWC

The Society of Gynecologic Oncology (SGO) and The GOG Foundation, Inc. (GOG-F) Launch the BRIDGES 2.0 Research Initiative with support from the Foundation for Women's Cancer (FWC).

After a successful inaugural year, the SGO and the GOG-F join forces to collaborate and proudly announce the launch of an expanded two-year clinical trial education program supported by the FWC. This important career and clinical trial development initiative aims to cultivate the next generation of investigators in gynecologic oncology and will focus on clinical and translational research advancements, trial methodology, and real world clinical trials implementation.

BRIDGES 2.0. is tailored for gynecologic oncologists, medical oncologists, and radiation oncologists in the early stages of their careers, including senior fellows and faculty members with less than ten years of experience post-training, to gain critical insights into clinical trial design fundamentals.

Applications are actively being accepted as of today. Interested candidates can find a comprehensive outline of application requirements on the BRIDGES webpage. Prospective applicants are encouraged to prepare submissions early to ensure receipt by the **deadline of Thursday, May 16, 2024.**

The selected cohort of BRIDGES 2.0 scholars will begin their program engagement in July 2024 at the NRG Semi-Annual Meeting, July 25-27, 2024 in Denver, Colorado

[Click here](#) to read the full press release.



**APPLY TODAY**

**Have questions?**

Please reach out to [education@sgo.org](mailto:education@sgo.org).

The SGO, GOG-F and FWC wish to thank their generous BRIDGES 2.0 Research Initiative partners:

*Ovarian Cancer Research Alliance, AstraZeneca, GSK, Merck, and Seagen*

## CERVICAL CANCER GEO-ANALYZER

The Cervical Cancer Geo-Analyzer is an open access, web-based, interactive tool to visualize cervical cancer and r/mCC burden across different communities in the United States. The tool aims to help researchers, policy makers, and advocacy groups inform geographical areas in the United States where cervical cancer education or healthcare resource needs are high. For building the user interface, we utilized free and open-source ReactJS software.



"My hope is that the Cervical Cancer Geo-Analyzer will lead to a better understanding of geographic interactions and impact on how, where, and when patients get cancer treatments. To describe the unique barriers at geographic level such that resources, policy initiatives, and clinical trial portfolios can be tailored to specific community and regional needs," said Tara Castellano, MD, University Medical Center New Orleans Health, New Orleans, Louisiana, USA.

For additional information, please see the related article published in Gynecologic Oncology [here](#).

[Access the Geo-Analyzer](#)

## IN THE NEWS

### GOG-3091 (VB C-04) Press Release

#### Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Oslo, Norway, April 19, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company's off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche's checkpoint inhibitor atezolizumab (Tecentriq®) in patients with HPV16-positive, PD-L1-positive, recurrent, or metastatic cervical cancer.



[Click here](#) to view the full press release.

### ENGOT-EN6-NSGO / GOG-3031 RUBY Press Release

#### RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer

March 16, 2024 -- The European Network for Gynaecological Oncological Trial (ENGOT) groups, the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU) and the GOG Foundation, Inc. (GOG-F) are proud to collaborate with the study sponsor, GSK



in the RUBY Part 2 trial.

The results reveal improvement in progression-free survival (PFS) at 12 months in the overall study population from 33.7% (carboplatin/paclitaxel [CP]+placebo+placebo) to 57.0% (CP+dostarlimab+niraparib), and in MMRp/MSS population from 31.1% (CP+placebo+placebo) to 54.7% (CP+dostarlimab+niraparib).

[Click here](#) to view the full press release.

---

## ENGOT-cx11 / GOG-3047 KEYNOTE A-18 Press Release


**Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer**



March 15, 2024 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.

[Click here](#) to view the full press release.

Click the video below to watch the live interview from the 2024 SGO Annual Meeting on Women's Cancer® with Dr. Ginger Gardner and Dr. Leslie Randall discussing ENGOT-cx11 / GOG-3047 KEYNOTE A-18.



---

## GOG-3020/ENGOT-ov45 ATHENA-MONO Press Release

**pharma&'s Rubraca® (rucaparib) ATHENA-MONO Clinical Trial Data in First-Line Maintenance Treatment Suggest Benefit Continues Beyond Completion of Treatment and First Progression**



**Vienna, Austria, March 16, 2024** – pharmaand GmbH (pharma&) announced today the presentation of data from the randomized, Phase 3 Company-sponsored ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO) monotherapy versus placebo presented on Saturday, March 16, 2024, during the Society of Gynecologic Oncology (SGO) Annual Meeting held in San Diego, California, U.S.A. Dr. Rebecca S. Kristeleit MD, PhD, of Guy's and St Thomas' NHS Foundation Trust in London and lead ENGOT/NCRI National Cancer Research Institute (<https://www.ncri.org.uk/>) investigator of the ATHENA trial will present the oral presentation, "Interim Post-Progression Data and Updated Survival in Patients with Newly Diagnosed Advanced Ovarian Cancer in ATHENA-MONO."

[Click here](#) to view the full press release.

## SPECIAL RECOGNITION

### Kathleen Moore, MD, MS announced 2023 recipient of the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research

The 2023 recipient of the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research is Kathleen N. Moore, MD, MS, of the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma. Dr. Moore is being recognized for her remarkable leadership. She has not only been at the vanguard of novel therapeutic development that has impacted the standard of care for ovarian cancer patients but has also mentored dozens of clinical and translational investigators who have gone on to advance research through notable accomplishments of their own. She has also contributed extensively to the field as an author, with her work appearing in more than 400 peer-reviewed publications.



Dr. Moore is the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center. She also serves as the Associate Director of Clinical Research and Deputy Director of OU Health Stephenson Cancer Center.

The Rosalind Franklin Prize for Excellence in Ovarian Cancer Research is a \$10,000 annual prize in recognition of contributions to basic science, translational, or clinical research in ovarian cancer. It is named for Dr. Rosalind Franklin, a pioneering molecular biologist who played a vital role in discovering the structure of DNA before her death of ovarian cancer at age 37.

[Click here](#) to view the full article.

## CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 22 clinical trials

- **14 Ovary**
- **1 Cervix**
- **7 Endometrium**



To search active trials visit our website by clicking Clinical Trials button below.

[Clinical Trials](#)

## Top 50 Recruiting Sites GOG Partners/NRG Combined

1. The Ohio State University Comprehensive Cancer Center
2. University of Oklahoma Health Sciences Center
3. Women & Infants Hospital
4. University of Virginia
5. Memorial Sloan Kettering Cancer Center
6. NYU Langone Medical Center - NYU Clinical

- Cancer Center - Womens Cancer Program
7. Washington University School of Medicine
  8. Georgia Regents/Augusta University
  9. University of Rochester
  10. Oklahoma Cancer Specialists and Research Institute, LLC
  11. HonorHealth Research and Innovation Institute - USO
  12. Froedtert and The Medical College of Wisconsin
  13. University of Colorado Hospital - Anschutz Cancer Pavilion
  14. Virginia Commonwealth University
  15. Yale University
  16. Abington Memorial Hospital - Asplundh Cancer Pavilion/Thomas Jefferson
  17. University of Alabama at Birmingham
  18. University of Chicago Medical Center
  19. New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center
  20. Duke University Medical Center
  21. Western Pennsylvania Hospital/West Penn Hospital
  22. Trials365, LLC/WK Physicians Network/Gynecologic Oncology Associates
  23. Rutgers Cancer Institute of NJ
  24. UCLA Johnson Comprehensive Cancer Center
  25. The Blavatnik Family - Chelsea Medical Center at Mount Sinai
  26. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
  27. Cleveland Clinic Foundation
  28. University of Washington Fred Hutchinson Cancer Center (FHCC)/Seattle Cancer Care Alliance
  29. University of Cincinnati
  30. Arizona Oncology Associates, PC - HOPE - USO
  31. University of Iowa Hospitals and Clinics
  32. Texas Oncology - Fort Worth - USO
  33. Magee Women's Hospital - UPMC
  34. Advent Health Orlando
  35. Northwestern University
  36. Texas Oncology, P.A., San Antonio Medical Center - USO
  37. University of Pennsylvania
  38. Women's Cancer Care Associates, LLC
  39. Moffitt Cancer Center
  40. University of Texas Southwestern Medical Center
  41. Nebraska Methodist Hospital
  42. University of Wisconsin
  43. Indiana University
  44. University of Michigan
  45. Huntsman Cancer Institute
  46. Center of Hope
  47. Carilion Clinic Gynecologic Oncology
  48. Baystate Medical Center
  49. Avera Cancer Institute
  50. University of California San Diego Moores Cancer Center

GOG PARTNERS

NRG  
ONCOLOGY  
Advancing Research. Improving Lives.

*Congratulations*

**TOP 50 RECRUITING SITES**

GOG PARTNERS & NRG ONCOLOGY  
COMBINED ACCRUAL



## UPCOMING INDUSTRY MEETINGS

### ASCO Annual Meeting

**2024 ASCO**  
ANNUAL MEETING

The 2024 ASCO Annual Meeting will be held on **May 31 - June 4, 2024 in Chicago, IL**, at the McCormick Place Convention Center. This year's meeting is only available in person.

Join fellow oncology professionals at the 2024 ASCO Annual Meeting – a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in

global cancer care.

[Click Here](#) for more information on the ASCO Annual Meeting.

---

## WAGO Annual Meeting



**WAGO**  
Western Association of  
Gynecologic Oncology

The 2024 WAGO Annual Meeting will be held on **June 12 - 15, 2024 in Seattle, WA** at the Fairmont Olympic Hotel.

[Click Here](#) for more information on the WAGO Annual Meeting.

---

## ESMO Gynaecological Cancers Congress



The 2024 ESMO Gynaecological Cancers Congress will be held on **June 20-22, 2024 in Florence, Italy**.

ESMO Gynaecological Cancers has become an essential annual appointment for oncology professionals treating patients with such malignancies – the place to learn the latest promising news, acquire high quality education and exchange ideas.

[Click Here](#) for more information on the ESMO Gynaecological Cancers Annual Congress.

---

## NRG Summer Semi-Annual Meeting



The 2024 Summer NRG Semi-Annual Meeting will be held on **July 25 - 27, 2024 in Denver, CO** at the Sheraton Denver Downtown Hotel.

[Click Here](#) for more information on the NRG Semi-Annual Meeting.

---

## The GOG Highlight Reel - July 2024



The GOG Highlight Reel will be held on **Saturday July 27, 2024 in Denver, CO**, at the Sheraton Denver Downtown Hotel, in conjunction with the NRG Summer Semi-Annual Meeting.

---

## IGCS 2024 Annual Global Meeting



The IGCS 2024 Annual Global Meeting will be held on **October 16 - 18, 2024 in Dublin, Ireland**.

The IGCS Meeting is a platform for exchanging insights, sharing research findings, and discussing best practices. It's an opportunity to build professional networks, foster collaborations, and learn from some of the brightest minds in the field.

Don't miss the chance to be part of this global community striving to make a difference in the lives of women affected by gynecologic cancers!

[Click here](#) for more information on the IGCS 2024 Annual Global Meeting.

**IGCS 2024 abstract and surgical film deadline is April 30, 2024**


[Click here](#) to submit and contribute your research to IGCS 2024.

## Evolution of the Care of Patients With Advanced Ovarian Cancer

Join Drs. Ursula Matulonis and Brad Monk for a live, case-based webinar focusing on the frontline management of patients with advanced ovarian cancer. Treatment decision-making in ovarian cancer is becoming increasingly complex with the introduction of new therapies and modifications to indications of existing therapies.

Through the discussion of real-world case scenarios, Drs. Matulonis and Monk will review the latest clinical trial data, patient- and disease-related characteristics that influence treatment selection, identification and management of treatment-related adverse events, and shared decision-making. Don't miss this exciting activity!

[Click here](#) to access the recording.



## ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives

*an Industry Supported Symposium at the 2024 SGO Annual Meeting on Women's Cancer*

### Access to Symposium Recording

Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives symposium recording.


### Access to Symposium Presentations

Please [click here](#) to access the presentation files on the GOG Website.

### Course Objectives

- Review the current landscape for the treatment of recurrent cervix cancer based on pivotal clinical trial data and insights from 2023
- Understand the role of ADC in cervix cancer, and how to educate patients on this novel treatment option
- Review and incorporate updated data in treatment decision making through case based learning
- Understand the patient perspective with respect to receiving treatments in recurrent cervix cancer

*This symposium was developed by The GOG Foundation, Inc. in partnership with Seagen, Inc. and Genmab*





## MODERATOR



**Bhavana Pathuri, MD**  
NYU Langone  
Pelvic Cancer Center



**Susana Campos, MD, MPH**  
Dana-Farber Cancer Institute



**Kathleen Lutz, NP**  
NYU Langone  
Pelvic Cancer Center



**Leslie Randall, MD, MAS**  
Virginia Commonwealth University



**Andrea Kinloch**  
Patient Advocate

## FACULTY

## It's A Whole New World: Navigating Therapeutic Options for Endometrial Cancer Enduring Educational Materials

*an Industry Supported Symposium at the 2024 SGO Winter Meeting*

### Access to Symposium Recording

Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the It's a Whole New World: Navigating Therapeutic Options for Endometrial Cancer Enduring Educational Materials symposium recording.


### Access to Symposium Presentations

Please [click here](#) to access the presentation file on the GOG Website.

### Course Objectives:

- Review the current landscape for the treatment of advanced stage or recurrent endometrial cancer based on pivotal clinical trials and insights in 2023.
- Discuss biomarker-based strategies to direct chemotherapy, radiation, combined chemoradiation, and biologic-targeted therapies.
- Highlight novel therapies and current clinical trials for endometrial cancer.
- Decipher how to best treat patients based on debates and discussion from Expert Faculty.

*The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: AstraZeneca, GSK, and Karyopharm*



### It's A Whole New World: Navigating Therapeutic Options for Endometrial Cancer

An Industry Supported Symposium at the 2024 SGO Winter Meeting

AVAILABLE NOW

ENDURING  
EDUCATIONAL  
MATERIALS

Presented on January 25, 2024

GOG FOUNDATION<sup>®</sup>  
Supporting the Unmet Need

GOG PARTNERS



**Matthew Powell, MD**  
Washington University



**Amanda Nickles-Fader, MD**  
Johns Hopkins University



**Floor Backes, MD**  
The Ohio State University  
James Cancer Center

## The 3 E's of ICI in endometrial cancer: emergence, evolution, and expansion

*an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting*

ACCESS TO SYMPOSIUM RECORDING

Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the 3 E's of ICI in endometrial cancer: emergence, evolution, and expansion symposium recording.

### ACCESS TO SYMPOSIUM PRESENTATIONS

Please [click here](#) to access the presentation files on the GOG website

International Gynecologic Cancer Society 2023 Annual Global Meeting

### The 3 Es of ICI in endometrial cancer: emergence, evolution, and expansion

CHAIR



Dr. Byoung-Gie Kim    Dr. Jung-Yun Lee    Dr. Mansoor Raza Mirza    Dr. David SP Tan



This material was developed in compliance with the CME/CPD/FPD code. The material is included in the CME/CPD/FPD credit. ©2023 GOG group of companies or its licensors. All rights reserved. We care. For good. GOGOG. October 2023

Sponsored by **GSK**



**Byoung-Gie Kim, MD, PhD**  
Samsung Medical Center,  
Sungkyunkwan University School



**Jung-Yun Lee, MD, PhD**  
Yonsei University College of  
Medicine



**Mansoor Raza Mirza, MD**  
Rigshospitalet  
Copenhagen University Hospital



**David SP Tan, MBBS, PG Dip,  
MRCP, PhD, FRCP**  
National University Cancer  
Institute

## Target Practice: Zeroing in and Eliminating Ovarian Cancer. A course to review and understand the ADC opportunities that exist in Ovarian Cancer

*an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting*

### ACCESS TO SYMPOSIUM RECORDING

Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the Target Practice: Zeroing in and Eliminating Ovarian Cancer. A course to review and understand the ADC opportunities that exist in Ovarian Cancer symposium recording.


### ACCESS TO PRESENTATIONS

Please [click here](#) to access the presentation file on the GOG website.

### Course Objectives:

- Review and understand all ADC Opportunities that exist in ovarian cancer patient care management.
- Understand the components of each unique agent and how to mitigate any adverse reactions.
- Discuss ADC targets and how to prioritize targets for your patient.
- Outline the ongoing trials studying ADCs in Ovarian Cancer.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: *ImmunoGen, Mersana, and Novocure.*



**IGCS 2023**

**GOG FOUNDATION**  
Advancing the standard of care

### Enduring Educational Materials

**Target Practice: Zeroing in and Eliminating Ovarian Cancer. A course to review and understand the ADC opportunities that exist in Ovarian Cancer.**

An Industry Supported Symposium at the IGCS 2023 Annual Global Meeting.  
This session is not included in the main event CME/CPD credit.

**AVAILABLE NOW**



**Kathleen Moore, MD**  
University of Oklahoma,  
Stephenson Cancer Center, USA



**Linda Duska, MD**  
University of Virginia School of  
Medicine, USA



**Róisín O'Cearbhaill, MD**  
Memorial Sloan Kettering Cancer  
Center, USA



**Isabelle Ray-Couquard, MD, PhD**  
Centre Léon Bérard, France

## Join the Conversation: Incorporating Breakthrough Cervical Cancer Data into Practice

*an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting*

### TO ACCESS SYMPOSIUM RECORDING

Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the Join the Conversation: Incorporating Breakthrough Cervical Cancer Data into Practice symposium recording.

### TO ACCESS SYMPOSIUM PRESENTATIONS

Please [click here](#) to access the presentation files on the GOG website.


An Industry Supported Symposium  
by Seagen  
at the IGCS 2023 Annual Global Meeting



**Join the Conversation:**  
**Incorporating Breakthrough  
Cervical Cancer Data into Practice**

AVAILABLE NOW

**ENDURING  
EDUCATIONAL  
MATERIALS**




Presented  
5<sup>th</sup> November 2023

This session is not included in the main event CME/CPD credit.  
SEAGEN and its logos are trademarks of Seagen Inc., registered in the European Union and elsewhere. ©2023 Seagen Inc.  
USA. All rights reserved. Date of preparation: September 2023 | Merken Number: ASP/TVM/2023/0004



**Keiichi Fujiwara, MD, PhD**  
Saitama Medical University International  
Medical Center



**Domenica Lorusso, MD, PhD**  
Fondazione Policlinico Gemelli IRCCS



**Ana Oaknin, MD, PhD**  
Vall d'Herbron University Hospital (HUVH)



**Leslie Randall, MD**  
Massey Cancer Center,  
Virginia Commonwealth University



**Brian Slomovitz, MD**  
Mount Sinai Medical Center

## The Evolving Landscape in Molecular-Driven Investigational Therapies for Advanced Endometrial Cancer

*an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting*

### TO ACCESS SYMPOSIUM RECORDING

Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to The Evolving Landscape in Molecular-Driven Investigational Therapies for Advanced Endometrial Cancer symposium recording.

### TO ACCESS SYMPOSIUM PRESENTATIONS

Please [click here](#) to access the presentation files on the GOG website.

**IGCS 2023**

**Karyopharm**  
Therapeutics

*An Industry Supported Symposium at  
the IGCS 2023 Annual Global Meeting  
developed by Karyopharm in partnership with The GOG Foundation, Inc.*

**THE EVOLVING LANDSCAPE  
IN MOLECULAR-DRIVEN  
INVESTIGATIONAL  
THERAPIES FOR ADVANCED  
ENDOMETRIAL CANCER**

**ENDURING EDUCATIONAL MATERIALS**  
Available Online

**PRESENTED ON**  
November 6, 2023

**AVAILABLE NOW**

### Overview

This sixty-minute virtual symposium will discuss emerging molecular-driven therapeutics in

advanced endometrial cancer (EC). The overall goal is to educate on how molecular profiling is driving advancement in EC research and how the development landscape is evolving. Expert physicians will have a robust discussion to showcase the latest clinical trial data and potential impact on future treatment.



**Bradley J. Monk, MD**  
US Cancer Associates



**Domenica Lorusso, MD, PhD**  
University of Rome &  
Fondazione  
Policlinico Gemelli IRCCS



**Ritu Salani, MD, MS**  
UCLA Medical Center

## An Evolving Frontier - Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers

*an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting*

### First Presentation:

The Evolving Treatment Landscape for The Management of Endometrial Cancer

### Presented By:

Ramez N. Eskander, MD  
UC San Diego School of Medicine, San Diego, CA,  
USA

### How To Access The Recording

When viewing the recording, all registrants must sign in to Education360 Learning Portal with their IGCS username and password. If you receive email communications from IGCS, you already have an account.

If you have forgotten your password, please [click here](#).

For further assistance with your IGCS account, contact [igcs@igcs.org](mailto:igcs@igcs.org).

If you are unsure of your IGCS account login information, please contact [igcs@igcs.org](mailto:igcs@igcs.org).

*Eisai has sponsored this initiative with IGCS and had no input into or influence over the content.*

[View Recording](#)

**AN EVOLVING FRONTIER - UNDERSTANDING NOVEL TREATMENT OPTIONS FOR THE MANAGEMENT OF ADVANCED STAGE OR RECURRENT ENDOMETRIAL CANCERS**

*An Industry Supported Symposium at the IGCS 2023 Annual Global Meeting*

**FIRST PRESENTATION:**  
The Evolving Treatment Landscape for The Management of Endometrial Cancer

**Ramez Eskander, MD**  
UC San Diego Moores Comprehensive Cancer Center, USA

## PHILANTHROPY

### New Horizons Gynecologic Cancer Research Fund

The New Horizons Gynecologic Cancer Research Fund is



the philanthropic arm for The GOG Foundation, Inc. (GOG-F). Donations allow the GOG-F to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research programs.

Donations from individuals, corporations, and foundations directly fund the GOG-F educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:

- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

[Support Our Mission](#)

## LET'S GET SOCIAL

### What GOG Means to Me



“ ”  
GOG means research success and amazing people. GOG runs trials that provide novel effective treatments for patients with gynecologic malignancies. GOG is inclusive in mentoring our next generation of clinical trialists to be the best.

#### Thomas J. Herzog, MD

GOG Partners Associate Director  
Clinical Director

Paul & Carolyn Flory Professor in Gynecologic Oncology  
University of Cincinnati

**GOG** FOUNDATION<sup>®</sup>  
Translating the science of care

**GOG** PARTNERS  
A GOG Foundation Program

Participate in the “What GOG Means to ME” social media campaign!

Please email Lindsey Moeller at [lmoeller@gog.org](mailto:lmoeller@gog.org) and include the following information:

- Quote: No more than 35 words indicating what GOG means to you
- Current Headshot (Jpg or PNG format)
- Current Title/Role
- Institution
- Social Tags: Please provide how we can find you on each of the social platforms so we can tag you when we post.



## CONTACT US

### How Can We Help?

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at [info@gog.org](mailto:info@gog.org) with any questions or suggestions regarding future content.

[Unsubscribe cgaloppo@gog.org](#)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by [lmoeller@gog.org](mailto:lmoeller@gog.org) powered by



Try email marketing for free today!